Nikolay S. Markov

Jan 7, 2025 | nature.com | Connor H. Puritz |Karolina J. Senkow |Nikolay S. Markov |Estefani Diaz |Emmy Jonasson |Rogan A. Grant | +6 more

Correction to: Nature Immunology https://doi.org/10.1038/s41590-024-01975-x, published online 4 October 2024. In the version of this article initially published, there was a typographical error in the first paragraph of the Methods, where in the sentence now reading “Subsequent CT scans were obtained in 29 patients a median of 118 d (range 31–249 d) after the first CT scan,” the median was first reported as “11 d.” The error has been corrected in the HTML and PDF versions of the article.

Oct 4, 2024 | nature.com | Connor H. Puritz |Karolina J. Senkow |Nikolay S. Markov |Estefani Diaz |Emmy Jonasson |Rogan A. Grant | +6 more

AbstractMonocyte-derived alveolar macrophages drive lung injury and fibrosis in murine models and are associated with pulmonary fibrosis in humans. Monocyte-derived alveolar macrophages have been suggested to develop a phenotype that promotes lung repair as injury resolves.

Sep 10, 2024 | medrxiv.org | Nikolay S. Markov |Anna E. Pawlowski |Mengou Zhu |Chiagozie O Pickens

Declarations of interests: BDS holds US patent 10,905,706, "Compositions and methods to accelerate resolution of acute lung inflammation," and serves on the scientific advisory board of Zoe Biosciences, in which he holds stock options. Other authors declare no conflicts of interest. SCRIPT is supported by NIH/NIAID U19AI135964. CAG is supported by NIH/NHLBI K23HL169815, a Parker B. Francis Opportunity Award, and an ATS Unrestricted Grant.

Feb 12, 2024 | aicr.org | Nikolay S. Markov

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Feb 7, 2024 | medrxiv.org | Catherine Gao |Nikolay S. Markov |Anna E. Pawlowski |Chiagozie A. Pickens

BDS holds US patent 10,905,706, "Compositions and methods to accelerate resolution of acute lung inflammation," and serves on the Scientific Advisory Board of Zoe Biosciences, for which he holds stock options. Other authors declare no conflicting interests. SCRIPT is supported by NIH/NIAID U19AI135964. CAG is supported by NIH/NHLBI F32HL162377. BDS is supported by NIH awards R01HL149883, R01HL153122, P01HL154998, P01AG049665, and U19AI135964.